Jan19Tue

Member News from ICON Clinical Research

ICON Releases Flex Advantage to Enhance Patient Randomisation and Clinical Supply Management in Clinical Trials

Dublin, Ireland, 19th January, 2015 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced Flex Advantage, a next-generation Interactive Response Technology (IRT) platform that offers enhanced randomisation and clinical supply management capabilities and supports the execution of adaptive trials.

To read more, please click HERE.

Dec21Mon

Global Economic Forum 2016

IABCN Founder & Chairman Emeritus, Bill McLaughlin, participated in the 2016 Global Irish Economic Forum last month, the fourth such forum.

While previous Forums concentrated on recovery from the financial crisis, and rebuilding Ireland’s reputation internationally, this year the overarching theme was on sustaining and strengthening our robust economic growth into the future, with a particular focus on opportunities in high-potential sectors including financial services, research and innovation and international education.  It also focused on fostering entrepreneurship and supporting indigenous businesses to scale up, increase exports and create jobs at home. To learn more, please click HERE.

To read the November Global Irish Newsletter, please click HERE.

Bill McLaughlin, IABCN Founder, with Tom Arnold, Director General, Institute of International and European Affairs

Bill McLaughlin, IABCN Founder, with Tom Arnold, Director General, Institute of International and European Affairs

Dec09Wed

Member News from ICON

ICON Accelerates Site Activation Timelines by up to 25%

Cycle times reduced through process improvement and implementation of industry leading technology

Dublin, Ireland, 9 December, 2015 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has accelerated its study start-up timelines globally and has achieved a reduction of mean start-up cycle times by up to 25%.

Read More

Dec07Mon

Member News from ICON Clinical Research

ICON Acquires PMG Research Inc.

Acquisition enhances ICON’s site and patient engagement capabilities

Dublin, Ireland, 7th December, 2015 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced the acquisition of PMG Research, Inc., an integrated network of clinical research sites operating from 12 metropolitan areas throughout the US. The acquisition will enhance ICON’s ability to access and engage with investigator sites and patients, helping customers to reduce the overall time and cost associated with drug development. 

Read More